Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Willekens

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
European Journal of Haematology|September 21, 2024
Relevance, Risks, and Benefits of Early-Phases Clinical Trials Participations for Patients With Hematological Malignancies From 2008 to 2023Matteo Guerra, Emily Alouani, Thomas Hueso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2020
First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid LeukemiaOlga Salamero, Pau Montesinos, Christophe Willekens, et al.
European Journal of Cancer (Oxford, England : 1990)|August 10, 2015
Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal typeJean-Marie Michot, Renaud Mazeron, Alina Danu, et al.
Nature Communications|December 22, 2018
A miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subsetDorothée Selimoglu-Buet, Julie Rivière, Hussein Ghamlouch, et al.
Oncoimmunology|January 12, 2023
RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignanciesCamille Bigenwald, Yacine Haddad, Cassandra Thelemaque, et al.
Blood|April 9, 2015
Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemiaDorothée Selimoglu-Buet, Orianne Wagner-Ballon, Véronique Saada, et al.
Hemasphere|August 23, 2021
Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast CancersSabine Khalife-Hachem, Khalil Saleh, Florence Pasquier, et al.
Cancer Cell|March 6, 2018
ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute LeukemiaTamara Maes, Cristina Mascaró, Iñigo Tirapu, et al.
Leukemia|June 24, 2025
Comparison of induction with arsenic trioxide or chemotherapy in a real-world cohort of patients with high-risk acute promyelocytic leukemiaDelphine Lebon, Audrey Da Rocha, Bruno Cassinat, et al.
Leukemia|March 22, 2019
Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemiaNolwenn Lucas, Matthieu Duchmann, Philippe Rameau, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
European Journal of Haematology|September 21, 2024
Relevance, Risks, and Benefits of Early-Phases Clinical Trials Participations for Patients With Hematological Malignancies From 2008 to 2023Matteo Guerra, Emily Alouani, Thomas Hueso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2020
First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid LeukemiaOlga Salamero, Pau Montesinos, Christophe Willekens, et al.
European Journal of Cancer (Oxford, England : 1990)|August 10, 2015
Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal typeJean-Marie Michot, Renaud Mazeron, Alina Danu, et al.
Nature Communications|December 22, 2018
A miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subsetDorothée Selimoglu-Buet, Julie Rivière, Hussein Ghamlouch, et al.
Oncoimmunology|January 12, 2023
RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignanciesCamille Bigenwald, Yacine Haddad, Cassandra Thelemaque, et al.
Blood|April 9, 2015
Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemiaDorothée Selimoglu-Buet, Orianne Wagner-Ballon, Véronique Saada, et al.
Hemasphere|August 23, 2021
Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast CancersSabine Khalife-Hachem, Khalil Saleh, Florence Pasquier, et al.
Cancer Cell|March 6, 2018
ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute LeukemiaTamara Maes, Cristina Mascaró, Iñigo Tirapu, et al.
Leukemia|June 24, 2025
Comparison of induction with arsenic trioxide or chemotherapy in a real-world cohort of patients with high-risk acute promyelocytic leukemiaDelphine Lebon, Audrey Da Rocha, Bruno Cassinat, et al.
Leukemia|March 22, 2019
Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemiaNolwenn Lucas, Matthieu Duchmann, Philippe Rameau, et al.
Pageof 5